Soligenix provides regulatory update on hybryte™

Princeton, n.j. , april 14, 2023 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the company convened a type a meeting with the united states (u.s.) food and drug administration (fda).
SNGX Ratings Summary
SNGX Quant Ranking